Curis, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Curis, Inc. Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize innovative small-molecule drug candidates targeting dysregulated signaling pathways in cancer, primarily focused on hematologic malignancies and select solid tumors; its lead product candidate is emavusertib (CA-4948), an orally available small-molecule inhibitor of IRAK4 kinase and FLT3 (in certain contexts), evaluated in multiple ongoing Phase 1/2 clinical trials including the TakeAim Lymphoma study in relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with ibrutinib, the TakeAim Leukemia study as monotherapy in relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (hrMDS), and frontline AML triplet combinations with venetoclax and azacitidine; the pipeline also includes fimepinostat (CUDC-907), an oral dual HDAC/PI3K inhibitor for MYC-altered cancers such as relapsed/refractory diffuse large B-cell lymphoma; immune checkpoint antagonists CA-327 (TIM3/PD-L1 bispecific) and CA-170 (VISTA/PD-L1 bispecific) for PDL1/TIM3- or PDL1/VISTA-expressing cancers; and royalty revenues from Erivedge (vismodegib, hedgehog pathway inhibitor) commercialized by Genentech, a member of the Roche Group, for advanced basal cell carcinoma. Founded in 2000 and headquartered in Lexington, Massachusetts, the company conducts operations primarily in the United States through preclinical research, clinical development, and strategic collaborations such as its 2015 exclusive license agreement with Aurigene Discovery Technologies Limited for emavusertib and related IRAK4 inhibitors. Recent developments include completion of enrollment in the TakeAim Leukemia Phase 1/2 monotherapy study with follow-up ongoing and initial data from the frontline AML triplet study showing 50% MRD conversion in evaluable patients; continued enrollment in TakeAim Lymphoma Parts B and C (BTKi-experienced and naïve PCNSL cohorts) to support potential accelerated approval filings in the US and EU, with updated PCNSL/SCNSL data presented at the 2025 Society for Neuro-Oncology meeting; filing of a protocol with the FDA and site activation for a new Phase 2 study of emavusertib plus BTKi in relapsed/refractory chronic lymphocytic leukemia (CLL) targeting complete remission, uMRD, and time-limited therapy, with first patient dosing expected late Q4 2025 or early Q1 2026 and data at ASH 2026; a $7.0 million registered direct offering and concurrent private placement in July 2025 extending cash runway into Q1 2026; and initial data from an investigator-sponsored Phase 1 study of emavusertib with gemcitabine/nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma slated for ASCO GI 2026.
Curis Consents First Six Patients in TakeAim CLL Study
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Curis Provides First Quarter 2026 Business Update
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Curis Provides Fourth Quarter 2025 Business Update
SecurityBridge Releases the Cybersecurity Resilience Index for SAP (CRIS) to Set the Standard for SAP Security Maturity Benchmarking
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS)
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Curis Provides Updated Data from its Frontline AML Triplet Study
Curis to Present at Upcoming 30th Annual SNO Meeting
Curis, Inc. (CRIS) Q3 2025 Earnings Call Transcript
Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates
Curis Provides Third Quarter 2025 Business Update